Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 8/20 | 0.61 |
| ▸ | NPY1R | P25929 | 4/20 | 0.61 |
| ▸ | NPY2R | P49146 | 4/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.61 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 9/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794137 | 0.95 | GHSR (0.57) | NPY4RNPY1RNPY2RNPY5RNPBWR1 | |
| SCHEMBL30401893 | 0.95 | NPBWR1 (0.63) | NPY4RNPY1RNPY2RNPY5RNPBWR1 | |
| SCHEMBL30118086 | 0.94 | GHSR (0.57) | NPY4RNPY1RNPY2RNPY5RNPBWR1 | |
| SCHEMBL30464865 | 0.94 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL30773914 | 0.94 | GHSR (0.57) | NPY4RNPY1RNPY2RNPY5RNPBWR1 | |
| SCHEMBL29641180 | 0.94 | GHSR (0.58) | NPY4RNPY1RNPY2RNPY5RNPBWR1 | |
| SCHEMBL30093020 | 0.93 | NPBWR1 (0.56) | NPY4RNPY1RNPY2RNPY5RNPBWR1 | |
| SCHEMBL30464857 | 0.93 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29641066 | 0.91 | GHSR (0.61) | NPY4RNPY1RNPY2RGHSR | |
| SCHEMBL29641082 | 0.91 | GHSR (0.61) | NPY4RNPY1RNPY2RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12447142-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2025-10-21 | — | — | US | disclosed |
| EP-3655015-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | UNIV COLORADO REGENTS (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230233517-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | TSINGHUA UNIVERSITY (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11452709-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447142-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | CTSE, CTSB, ATG4B | NPY4R 1722/4885NPY1R 4375/4885NPY2R 4609/4885 |
| US-11452709-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | CTSE, CTSB, ATG4B | NPY4R 1722/4885NPY1R 4375/4885NPY2R 4609/4885 |
| US-20230233517-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | CTSE, CTSB, ATG4B | NPY4R 1722/4885NPY1R 4375/4885NPY2R 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.